Overview
No overview information available.
Background
No background information available.
Indication
用于治疗感染人类免疫缺陷病毒1型(HIV-1)的成人和12岁以上青少年（体重至少40kg），且对整合酶抑制剂或拉米夫定无已知或可疑耐药患者。
Associated Conditions
No associated conditions information available.
Clinical Trials
Title | Posted | Study ID | Phase | Status | Sponsor |
|---|---|---|---|---|---|
2025/06/22 | Phase 4 | Recruiting | |||
2024/09/30 | N/A | Recruiting | |||
2024/08/30 | Phase 4 | Not yet recruiting | Saskatchewan Health Authority - Regina Area | ||
2024/06/05 | Phase 3 | Active, not recruiting | |||
2023/06/26 | Phase 3 | Active, not recruiting | |||
2023/06/22 | Phase 3 | Active, not recruiting | |||
2022/09/22 | Phase 4 | Completed | |||
2021/07/28 | Phase 3 | UNKNOWN | Societa' Italiana Di Malattie Infettive E Tropicali | ||
2021/04/01 | Phase 1 | Completed |
FDA Drug Approvals
Approved Product | Manufacturer | NDC Code | Route | Strength | Effective Date |
|---|---|---|---|---|---|
| No FDA approvals found for this drug. | |||||
EMA Drug Approvals
Approved Product | Authorization Holder | Status | Issued Date |
|---|---|---|---|
| No EMA approvals found for this drug. | |||
HSA Drug Approvals
Approved Product | Manufacturer | Approval Number | Dosage Form | Strength | Approval Date |
|---|---|---|---|---|---|
| No HSA approvals found for this drug. | |||||
NMPA Drug Approvals
Approved Product | Company | Approval Number | Drug Type | Dosage Form | Approval Date |
|---|---|---|---|---|---|
| Lamivudine and Dolutegravir Sodium Tablets | 国药准字HJ20210013 | 化学药品 | 片剂 | 3/2/2021 |
PPB Drug Approvals
Approved Product | Registration No. | Company | Licence No. | Strength | Registration Date |
|---|---|---|---|---|---|
| No PPB approvals found for this drug. | |||||
TGA Drug Approvals
Approved Product | ARTG ID | Sponsor | Registration Type | Status | Registration Date |
|---|---|---|---|---|---|
| No TGA approvals found for this drug. | |||||